VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC CongressGlobeNewsWire · Oct 13, 2026
Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It?Barrons · Oct 7, 2026
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D StrategyGlobeNewsWire · Oct 7, 2026
VERAXA Biotech Appoints Raju Willener as Chief Financial OfficerGlobeNewsWire · Sep 4, 2026
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product CandidatesGlobeNewsWire · Jul 29, 2026
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAbGlobeNewsWire · Jul 27, 2026Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.